A ribonuclease zymogen activated by the NS3 protease of the hepatitis C virus

FEBS Journal

Volumn 273, Issue 23, 2006, Pages 5457-5465

  Johnson, R J ^a   Lin, Shawn R ^a   Raines, Ronald T ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Circular permutation; Ribonuclease A; Ribonuclease inhibitor; RNA virus

Indexed keywords

ENZYME PRECURSOR; NONSTRUCTURAL PROTEIN 3; PANCREATIC RIBONUCLEASE; RIBONUCLEASE; VIRUS ENZYME;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL STRAIN K 562; CONFORMATION; CONTROLLED STUDY; DRUG ACTIVATION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CATTLE; CIRCULAR DICHROISM; ENZYME ACTIVATION; ENZYME INHIBITORS; ENZYME PRECURSORS; HEPACIVIRUS; MODELS, MOLECULAR; PEPTIDE HYDROLASES; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; RIBONUCLEASE, PANCREATIC; TEMPERATURE; VIRAL NONSTRUCTURAL PROTEINS;

BOS TAURUS; HEPATITIS C VIRUS; MAMMALIA; RNA VIRUSES;

EID: 33751112474     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2006.05536.x     Document Type: Article

References (52)

1. Neurath H (1984) Evolution of proteolytic enzymes. Science 224, 350-357.
2. Salvesen GS & Abrams JM (2004) Caspase activation: stepping on the gas or releasing the brakes? Lessons from humans and flies. Oncogene 23, 2774-2784.
3. Khan AR & James MN (1998) Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes. Protein Sci 7, 815-836.
4. Borgono CA & Diamandis EP (2004) The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 4, 876-890.
5. Freer ST, Kraut J, Robertus JD, Wright HT & Xuong NH (1970) Chymotrypsinogen: 2.5-Å crystal structure, comparison with α-chymotrypsin, and implications for zymogen activation. Biochemistry 9, 1997-2009.
6. Kossiakoff AA, Chambers JL, Kay LM & Stroud RM (1977) Structure of bovine trypsinogen at 1.9 Å resolution. Biochemistry 16, 654-664.
7. Haigis MC, Kurten EL & Raines RT (2003) Ribonuclease inhibitor as an intracellular sentry. Nucleic Acids Res 31, 1024-1032.
8. Dickson KA, Haigis MC & Raines RT (2005) Ribonuclease inhibitor: structure and function. Prog Nucleic Acid Res Mol Biol 80, 349-374.
9. Lee FS, Shapiro R & Vallee BL (1989) Tight-binding inhibition of angiogenin and ribonuclease A by placental ribonuclease inhibitor. Biochemistry 28, 225-230.
10. Cuchillo CM, Vilanova M & Nogués MV (1997) Pancreatic ribonucleases. In Ribonucleases: Structures and Functions (D'Alessio G & Riordan JF, eds), pp. 271-304. Academic Press, New York, NY.
11. Raines RT (1998) Ribonuclease A. Chem Rev 98, 1045-1065.
12. Matoušek J (2001) Ribonucleases and their antitumor activity. Comp Biochem Physiol 129C, 175-191.
13. Leland PA & Raines RT (2001) Cancer chemotherapy: ribonucleases to the rescue. Chem Biol 8, 405-413.
14. Makarov AA & Ilinskaya ON (2003) Cytotoxic ribonucleases: molecular weapons and their targets. FEBS Lett 540, 15-20.
15. Loverix S & Steyaert J (2003) Ribonucleases and their anti-tumor activity. Comp Biochem Physiol 129C, 175-191.
16. Arnold U & Ulbrich-Hofmann R (2006) Natural and engineered ribonucleases as potential cancer therapeutics. Biotechnol Lett 28, 1615-1622.
17. Plainkum P, Fuchs SM, Wiyakrutta S & Raines RT (2003) Creation of a zymogen. Nat Struct Biol 10, 115-119.
18. Major ME, Rehermann B & Feinstone SM (2001) Hepatitis C viruses. In Fields Virology (Knipe, DM & Howley, PM, eds), 4th edn, pp. 1127-1161. Lippincott, Williams & Wilkins, New York, NY.
19. Lindenbach BD & Rice CM (2005) Unravelling hepatitis C virus replication from genome to function. Nature 436, 933-938.
20. Lindenbach BD & Rice CM (2001) Flaviviridae: the viruses and their replication. In Fields Virology (Knipe, DM & Howley, PM, eds), 4th edn, pp. 991-1041. Lippincott, Williams & Wilkins, New York, NY.
21. Burke DS & Monath TP (2001) Flaviviruses. In Fields Virology (Knipe, DM & Howley, PM, eds), pp. 1043-1125. Lippincott, Williams & Wilkins, New York, NY.
22. World Health Organization (1999) Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 6, 35-47.
23. Fishman JA, Rubin RH, Koziel MJ & Periera BJ (1996) Hepatitis C virus and organ transplantation. Transplantation 62, 147-154.
24. Tomei L, Failla C, Santolini E, De Francesco R & La Monica N (1993) NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J Virol 67, 4017-4026.
25. Zhang R, Durkin J, Windsor WT, McNemar C, Ramanathan L & Le HV (1997) Probing the substrate specificity of hepatitis C virus NS3 serine protease by using synthetic peptides. J Virol 71, 6208-6213.
26. Urbani A, Bianchi E, Narjes F, Tramontano A, De Francesco R, Steinkuhler C & Pessi A (1997) Substrate specificity of the hepatitis C virus serine protease NS3. J Biol Chem 272, 9204-9209.
27. Gordon CP & Keller PA (2006) Control of hepatitis C: a medical chemistry perspective. J Med Chem 48, 1-20.
28. Zhang R & Snyder GH (1989) Dependence of formation of small disulfide loops in two-cysteine peptides on the number and types of intervening amino acids. J Biol Chem 264, 18472-18479.
29. Klink TA & Raines RT (2000) Conformational stability is a determinant of ribonuclease A cytotoxicity. J Biol Chem 275, 17463-17467.
30. Leland PA, Schultz LW, Kim B-M & Raines RT (1998) Ribonuclease A variants with potent cytotoxic activity. Proc Natl Acad Sci USA 98, 10407-10412.
31. Smith BD, Soellner MB & Raines RT (2003) Potent inhibition of ribonuclease A by oligo (vinylsulfonic acid). J Biol Chem 278, 20934-20938.
32. Riddles PW, Blakeley RL & Zerner B (1983) Reassessment of Ellman's reagent. Methods Enzymol 91, 49-60.
33. Park C & Raines RT (2001) Adjacent cysteine residues as a redox switch. Protein Eng 14, 939-942.
34. Kelly SM, Jess TJ & Price NC (2005) How to study proteins by circular dichroism. Biochim Biophys Acta 1751, 119-139.
35. Kobe B & Deisenhofer J (1995) A structural basis of the interactions between leucine-rich repeats and protein ligands. Nature 374, 183-186.
36. Abel RL, Haigis MC, Park C & Raines RT (2002) Fluorescence assay for the binding of ribonuclease A to the ribonuclease inhibitor protein. Anal Biochem 306, 100-107.
37. Rutkoski TJ, Kurten EL, Mitchell JC & Raines RT (2005) Disruption of shape-complementarity markers to create cytotoxic variants of ribonuclease A. J Mol Biol 354, 41-54.
38. Sohl JL, Shiau AK, Rader SD, Wilk BJ & Agard DA (1997) Inhibition of α-lytic protease by pro region C-terminal steric occlusion of the active site. Biochemistry 36, 3894-3902.
39. Tan SL, Pause A, Shi Y & Sonenberg N (2002) Hepatitis C therapeutics: current status and emerging strategies. Nat Rev Drug Discov 1, 867-881.
40. Pizzi E, Tramontano A, Tomei L, La Monica N, Failla C, Sardana M, Wood T & De Francesco R (1994) Molecular model of the specificity pocket of the hepatitis C virus protease: implications for substrate recognition. Proc Natl Acad Sci USA 91, 888-892.
41. Kim JL, Morgenstern KA, Lin C, Fox T, Dwyer MD, Landro JA, Chambers SP, Markland W, Lepre CA, O'Malley ET, et al. (1996) Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87, 343-355.
42. Yao N, Reichert P, Taremi SS, Prosise WW & Weber PC (1999) Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Struct Fold Des 7, 1353-1363.
43. Thompson JE, Kutateladze TG, Schuster MC, Venegas FD, Messmore JM & Raines RT (1995) Limits to catalysis by ribonuclease A. Bioorg Chem 23, 471-481.
44. Bretscher LE, Abel RL & Raines RT (2000) A ribonuclease A variant with low catalytic activity but high cytotoxicity. J Biol Chem 275, 9893-9896.
45. Haigis MC, Haag ES & Raines RT (2002) Evolution of ribonuclease inhibitor protein by exon duplication. Mol Biol Evol 19, 960-964.
46. Blight KJ, Kolykhalov AA & Rice CM (2000) Efficient initiation of HCV RNA replication in cell culture. Science 290, 1972-1974.
47. Lohmann V, Korner F, Koch J, Herian U, Theilmann L & Bartenschlager R (1999) Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285, 110-113.
48. Taremi SS, Beyer B, Maher M, Yao N, Prosise W, Weber PC & Malcolm BA (1998) Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease. Protein Sci 7, 2143-2149.
49. Lee JE & Raines RT (2003) Contribution of active-site residues to the function of onconase, a ribonuclease with antitumoral activity. Biochemistry 42, 11443-11450.
50. Klink TA, Vicentini AM, Hofsteenge J & Raines RT (2001) High-level soluble production and characterization of porcine ribonuclease inhibitor. Protein Expr Purif 22, 174-179.
51. Wlodawer A, Svensson LA, Sjölin L & Gilliland GL (1988) Structure of phosphate-free ribonuclease A refined at 1.26 Å. Biochemistry 27, 2705-2717.
52. Vicentini AM, Kieffer B, Mathies R, Meyhack B, Hemmings BA, Stone SR & Hofsteenge J (1990) Protein chemical and kinetic characterization of recombinant porcine ribonuclease inhibitor expressed in Saccharomyces cerevisiae. Biochemistry 29, 8827-8834.